CeleramAb, which markets reagent and software kits designed to help pharmaceutical companies analyze complex biological data more quickly, has developed a direct infusion technology that streamlines peptide mapping data collection and analysis, accelerating the method by up to 100-fold, the company announced recently.

“Once (drug companies) get familiar and comfortable with our process, we anticipate even more of these experiments being done,” CeleramAb Co-Founder Joshua Coon said in a statement. “That’s going to not just save the company money, but it’s going to accelerate their ability to move drugs through the pipeline. That’s going to help everybody.”

The technology was developed through research at the University of Wisconsin and the Morgridge Institute for Research. In May, CeleramAb researchers published a paper in bioRxiv outlining the company’s direct infusion technology.

According to a Morgridge Institute story, the project also received support from UW’s Discovery to Product (D2P) and the Draper Technology Innovation Fund.